A Better Prognosis for Big Pharma
Concerns remain, but new products, improving R&D, and the continued validity of major patents may have eased the industry's ratings slide
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
You might like: